Overview

A Long-Term, Open-Label, Study on Schizophrenia

Status:
Terminated

Trial end date:
2012-10-01

Target enrollment:

Participant gender:

Summary

The primary purpose of the study is to help answer the following research questions: How LY 2140023 can be tolerated by patients with Schizophrenia compared to standard of care treatment in 52 weeks time period. Whether LY 2140023 can help patients with Schizophrenia.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Aripiprazole
Olanzapine
Quetiapine Fumarate
Risperidone